vs

Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and Ultra Clean Holdings, Inc. (UCTT). Click either name above to swap in a different company.

Ultra Clean Holdings, Inc. is the larger business by last-quarter revenue ($533.7M vs $321.1M, roughly 1.7× MADRIGAL PHARMACEUTICALS, INC.). Ultra Clean Holdings, Inc. runs the higher net margin — -2.8% vs -18.2%, a 15.4% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 2.9%).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

Ultra Clean Holdings, Inc. is a leading global supplier of critical subsystems, ultra-high purity cleaning services, and precision process components for the semiconductor, advanced display, and life sciences sectors. It operates across North America, Asia, and Europe, serving top semiconductor fabs and high-tech equipment manufacturers to support advanced microelectronics production.

MDGL vs UCTT — Head-to-Head

Bigger by revenue
UCTT
UCTT
1.7× larger
UCTT
$533.7M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+207.9% gap
MDGL
210.8%
2.9%
UCTT
Higher net margin
UCTT
UCTT
15.4% more per $
UCTT
-2.8%
-18.2%
MDGL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MDGL
MDGL
UCTT
UCTT
Revenue
$321.1M
$533.7M
Net Profit
$-58.6M
$-15.0M
Gross Margin
12.2%
Operating Margin
-18.6%
2.1%
Net Margin
-18.2%
-2.8%
Revenue YoY
210.8%
2.9%
Net Profit YoY
1.4%
-500.0%
EPS (diluted)
$-2.55
$-0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDGL
MDGL
UCTT
UCTT
Q1 26
$533.7M
Q4 25
$321.1M
$506.6M
Q3 25
$287.3M
$510.0M
Q2 25
$212.8M
$518.8M
Q1 25
$137.3M
$518.6M
Q4 24
$103.3M
$563.4M
Q3 24
$62.2M
$540.4M
Q2 24
$516.1M
Net Profit
MDGL
MDGL
UCTT
UCTT
Q1 26
$-15.0M
Q4 25
$-58.6M
$-3.3M
Q3 25
$-114.2M
$-10.9M
Q2 25
$-42.3M
$-162.0M
Q1 25
$-73.2M
$-5.0M
Q4 24
$-59.4M
$16.3M
Q3 24
$-107.0M
$-2.3M
Q2 24
$19.1M
Gross Margin
MDGL
MDGL
UCTT
UCTT
Q1 26
12.2%
Q4 25
15.2%
Q3 25
16.1%
Q2 25
15.3%
Q1 25
96.7%
16.2%
Q4 24
16.3%
Q3 24
17.3%
Q2 24
17.1%
Operating Margin
MDGL
MDGL
UCTT
UCTT
Q1 26
2.1%
Q4 25
-18.6%
2.2%
Q3 25
-39.7%
2.1%
Q2 25
-22.2%
-27.3%
Q1 25
-57.8%
2.5%
Q4 24
-64.8%
4.6%
Q3 24
-187.1%
4.7%
Q2 24
4.4%
Net Margin
MDGL
MDGL
UCTT
UCTT
Q1 26
-2.8%
Q4 25
-18.2%
-0.7%
Q3 25
-39.8%
-2.1%
Q2 25
-19.9%
-31.2%
Q1 25
-53.4%
-1.0%
Q4 24
-57.5%
2.9%
Q3 24
-172.0%
-0.4%
Q2 24
3.7%
EPS (diluted)
MDGL
MDGL
UCTT
UCTT
Q1 26
$-0.40
Q4 25
$-2.55
$-0.07
Q3 25
$-5.08
$-0.24
Q2 25
$-1.90
$-3.58
Q1 25
$-3.32
$-0.11
Q4 24
$-2.50
$0.36
Q3 24
$-4.92
$-0.05
Q2 24
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDGL
MDGL
UCTT
UCTT
Cash + ST InvestmentsLiquidity on hand
$198.7M
$323.5M
Total DebtLower is stronger
$339.9M
$601.9M
Stockholders' EquityBook value
$602.7M
$702.1M
Total Assets
$1.3B
$1.9B
Debt / EquityLower = less leverage
0.56×
0.86×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDGL
MDGL
UCTT
UCTT
Q1 26
$323.5M
Q4 25
$198.7M
$311.8M
Q3 25
$295.7M
$314.1M
Q2 25
$186.2M
$327.4M
Q1 25
$183.6M
$317.6M
Q4 24
$100.0M
$313.9M
Q3 24
$232.7M
$318.2M
Q2 24
$319.5M
Total Debt
MDGL
MDGL
UCTT
UCTT
Q1 26
$601.9M
Q4 25
$339.9M
$481.4M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
$499.7M
Q3 24
$117.1M
Q2 24
Stockholders' Equity
MDGL
MDGL
UCTT
UCTT
Q1 26
$702.1M
Q4 25
$602.7M
$711.0M
Q3 25
$625.7M
$709.9M
Q2 25
$696.0M
$719.4M
Q1 25
$710.6M
$872.0M
Q4 24
$754.4M
$873.6M
Q3 24
$777.2M
$857.9M
Q2 24
$852.3M
Total Assets
MDGL
MDGL
UCTT
UCTT
Q1 26
$1.9B
Q4 25
$1.3B
$1.7B
Q3 25
$1.4B
$1.7B
Q2 25
$1.0B
$1.7B
Q1 25
$996.6M
$1.9B
Q4 24
$1.0B
$1.9B
Q3 24
$1.1B
$1.9B
Q2 24
$1.9B
Debt / Equity
MDGL
MDGL
UCTT
UCTT
Q1 26
0.86×
Q4 25
0.56×
0.68×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
0.57×
Q3 24
0.15×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDGL
MDGL
UCTT
UCTT
Operating Cash FlowLast quarter
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDGL
MDGL
UCTT
UCTT
Q1 26
Q4 25
$-133.5M
$8.1M
Q3 25
$79.8M
$100.0K
Q2 25
$-47.1M
$29.2M
Q1 25
$-88.9M
$28.2M
Q4 24
$-104.5M
$17.1M
Q3 24
$-67.0M
$14.9M
Q2 24
$23.2M
Free Cash Flow
MDGL
MDGL
UCTT
UCTT
Q1 26
Q4 25
$-133.8M
$-2.0M
Q3 25
$79.0M
$-10.9M
Q2 25
$12.4M
Q1 25
$15.8M
Q4 24
$-104.7M
$-200.0K
Q3 24
$-67.8M
$-300.0K
Q2 24
$10.2M
FCF Margin
MDGL
MDGL
UCTT
UCTT
Q1 26
Q4 25
-41.7%
-0.4%
Q3 25
27.5%
-2.1%
Q2 25
2.4%
Q1 25
3.0%
Q4 24
-101.3%
-0.0%
Q3 24
-109.0%
-0.1%
Q2 24
2.0%
Capex Intensity
MDGL
MDGL
UCTT
UCTT
Q1 26
Q4 25
0.1%
2.0%
Q3 25
0.3%
2.2%
Q2 25
0.0%
3.2%
Q1 25
0.0%
2.4%
Q4 24
0.2%
3.1%
Q3 24
1.3%
2.8%
Q2 24
2.5%
Cash Conversion
MDGL
MDGL
UCTT
UCTT
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
1.05×
Q3 24
Q2 24
1.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

UCTT
UCTT

Products$465.7M87%
Services$68.0M13%

Related Comparisons